SCHEMBL31332789

SCHEMBL31332789

CCn1ccc(Cl)c1CSc1nc2c(c(OC)n1)CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 6/20 0.40
▸ GAA P10253 5/20 0.40
▸ LMNA P02545 4/20 0.40
▸ HTT P42858 4/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPT P10636 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ CYP2C9 P11712 1/20 0.33
▸ C5AR1 P21730 1/20 0.32
▸ TSHR P16473 2/20 0.32
▸ MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31332991 0.75 HPGD (0.60) LMNAMAPTHPGDKMT2AMEN1
SCHEMBL31332924 0.67 L3MBTL1 (0.39) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL8099775 0.65 KMT2A (0.48) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL26108416 0.63 L3MBTL1 (0.40) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL26110179 0.62 GAA (0.43) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL26106590 0.62 L3MBTL1 (0.39) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL26109798 0.62 L3MBTL1 (0.39) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL30606643 0.62 L3MBTL1 (0.39) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL26523772 0.60 KMT2A (0.42) L3MBTL1GAALMNAHTTSMN1; SMN2
SCHEMBL857447 0.60 L3MBTL1 (0.43) L3MBTL1GAALMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709374-A2 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-03-18 — — EP disclosed
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
WO-2024233885-A2 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF HCN2, HCN1, HCN4 L3MBTL1 3146/4885GAA 2314/4885LMNA 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback